These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
7. Evidence of Prostate-Specific Membrane Antigen Expression in Metastatic Differentiated Thyroid Cancer Using 68Ga-PSMA-HBED-CC PET/CT. Verma P; Malhotra G; Agrawal R; Sonavane S; Meshram V; Asopa RV Clin Nucl Med; 2018 Aug; 43(8):e265-e268. PubMed ID: 29894335 [TBL] [Abstract][Full Text] [Related]
8. Prostate-Specific Membrane Antigen Expression in Patients With Differentiated Thyroid Cancer With Thyroglobulin Elevation and Negative Iodine Scintigraphy Using 68Ga-PSMA-HBED-CC PET/CT. Verma P; Malhotra G; Meshram V; Chandak A; Sonavane S; Lila AR; Bandgar TR; Asopa RV Clin Nucl Med; 2021 Aug; 46(8):e406-e409. PubMed ID: 33883490 [TBL] [Abstract][Full Text] [Related]
9. F-18-Dopa Positron Emission Tomography/Computed Tomography Is More Sensitive Than Whole-Body Magnetic Resonance Imaging for the Localization of Persistent/Recurrent Disease of Medullary Thyroid Cancer Patients. Terroir M; Caramella C; Borget I; Bidault S; Dromain C; El Farsaoui K; Deandreis D; Grimaldi S; Lumbroso J; Berdelou A; Hadoux J; Hescot S; Hartl D; Baudin E; Schlumberger M; Leboulleux S Thyroid; 2019 Oct; 29(10):1457-1464. PubMed ID: 31530235 [No Abstract] [Full Text] [Related]
10. Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy. Rauscher I; Maurer T; Beer AJ; Graner FP; Haller B; Weirich G; Doherty A; Gschwend JE; Schwaiger M; Eiber M J Nucl Med; 2016 Nov; 57(11):1713-1719. PubMed ID: 27261524 [TBL] [Abstract][Full Text] [Related]
11. The role of 68Ga-PSMA PET/CT scan in biochemical recurrence after primary treatment for prostate cancer: a systematic review of the literature. Eissa A; Elsherbiny A; Coelho RF; Rassweiler J; Davis JW; Porpiglia F; Patel VR; Prandini N; Micali S; Sighinolfi MC; Puliatti S; Rocco B; Bianchi G Minerva Urol Nefrol; 2018 Oct; 70(5):462-478. PubMed ID: 29664244 [TBL] [Abstract][Full Text] [Related]
13. van Boxtel W; Lütje S; van Engen-van Grunsven ICH; Verhaegh GW; Schalken JA; Jonker MA; Nagarajah J; Gotthardt M; van Herpen CML Theranostics; 2020; 10(5):2273-2283. PubMed ID: 32089741 [No Abstract] [Full Text] [Related]
14. Biphasic ⁶⁸Ga-PSMA-HBED-CC-PET/CT in patients with recurrent and high-risk prostate carcinoma. Sahlmann CO; Meller B; Bouter C; Ritter CO; Ströbel P; Lotz J; Trojan L; Meller J; Hijazi S Eur J Nucl Med Mol Imaging; 2016 May; 43(5):898-905. PubMed ID: 26563122 [TBL] [Abstract][Full Text] [Related]
15. Visualization of Tumor Heterogeneity in Advanced Medullary Thyroid Carcinoma by Dual-Tracer Molecular Imaging: Revealing the Theranostic Potential of SSTR- and PSMA-Directed Endoradiotherapy. Hasenauer N; Higuchi T; Deschler-Baier B; Hartrampf PE; Pomper MG; Rowe SP; Fassnacht M; Buck AK; Werner RA Clin Nucl Med; 2022 Jul; 47(7):651-652. PubMed ID: 35085172 [TBL] [Abstract][Full Text] [Related]
16. Pilot Comparison of ⁶⁸Ga-RM2 PET and ⁶⁸Ga-PSMA-11 PET in Patients with Biochemically Recurrent Prostate Cancer. Minamimoto R; Hancock S; Schneider B; Chin FT; Jamali M; Loening A; Vasanawala S; Gambhir SS; Iagaru A J Nucl Med; 2016 Apr; 57(4):557-62. PubMed ID: 26659347 [TBL] [Abstract][Full Text] [Related]
17. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Afshar-Oromieh A; Avtzi E; Giesel FL; Holland-Letz T; Linhart HG; Eder M; Eisenhut M; Boxler S; Hadaschik BA; Kratochwil C; Weichert W; Kopka K; Debus J; Haberkorn U Eur J Nucl Med Mol Imaging; 2015 Feb; 42(2):197-209. PubMed ID: 25411132 [TBL] [Abstract][Full Text] [Related]